Home/Filings/4/0001439222-21-000057
4//SEC Filing

Bowden Christopher 4

Accession 0001439222-21-000057

CIK 0001439222other

Filed

Jun 10, 8:00 PM ET

Accepted

Jun 11, 5:00 PM ET

Size

14.3 KB

Accession

0001439222-21-000057

Insider Transaction Report

Form 4
Period: 2021-06-09
Bowden Christopher
Chief Medical Officer
Transactions
  • Sale

    Common stock

    2021-06-09$60.16/sh7,149$430,11715,487 total
  • Exercise/Conversion

    Common stock

    2021-06-10$39.76/sh+20,853$829,11536,340 total
  • Sale

    Common stock

    2021-06-10$60.06/sh20,853$1,252,43715,487 total
  • Exercise/Conversion

    Stock option (right to buy)

    2021-06-1020,8534,387 total
    Exercise: $39.76Exp: 2026-02-15Common stock (20,853 underlying)
  • Exercise/Conversion

    Common stock

    2021-06-09$39.76/sh+7,149$284,24422,636 total
  • Exercise/Conversion

    Stock option (right to buy)

    2021-06-097,14925,240 total
    Exercise: $39.76Exp: 2026-02-15Common stock (7,149 underlying)
Footnotes (5)
  • [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F5]This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001608601

Filing Metadata

Form type
4
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 5:00 PM ET
Size
14.3 KB